$EOLS
Evolus, Inc. Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000157056222000102 Filed on May 10, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$33.91M	$12.24M
YoY Change	177.0%	16.63%
Cost Of Revenue	$13.21M	$4.908M
YoY Change	169.11%	16.33%
Gross Profit	$20.70M	$7.333M
YoY Change	182.29%	16.82%
Gross Profit Margin	61.05%	59.91%
Selling, General & Admin	$33.44M	$20.67M
YoY Change	61.83%	-33.98%
% of Gross Profit	161.56%	281.81%
Research & Development	$468.0K	$841.0K
YoY Change	-44.35%	65.88%
% of Gross Profit	2.26%	11.47%
Depreciation & Amortization	$922.0K	$2.033M
YoY Change	-54.65%	16.24%
% of Gross Profit	4.45%	27.72%
Operating Expenses	$33.91M	$21.51M
YoY Change	57.68%	-9.15%
Operating Profit	-$15.45M	$8.026M
YoY Change	-292.47%	-146.14%
Interest Expense	$2.048M	$645.0K
YoY Change	217.52%	-131.01%
% of Operating Profit		8.04%
Other Income/Expense, Net	-$7.000K	$0.00
YoY Change		-100.0%
Pretax Income	-$17.50M	$6.413M
YoY Change	-372.93%	-132.92%
Income Tax	-$2.000K	$12.00K
% Of Pretax Income		0.19%
Net Earnings	-$17.50M	$6.401M
YoY Change	-373.41%	-132.43%
Net Earnings / Revenue	-51.61%	52.29%
Basic Earnings Per Share	-$0.31	$0.17
Diluted Earnings Per Share	-$0.31	$0.16
COMMON SHARES
Basic Shares Outstanding	55.73M shares	37.10M shares
Diluted Shares Outstanding	55.73M shares	41.10M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$106.7M	$22.17M
YoY Change	381.13%	-77.75%
Cash & Equivalents	$106.7M	$22.17M
Short-Term Investments		$0.00
Other Short-Term Assets	$11.31M	$6.728M
YoY Change	68.09%	86.89%
Inventory	$3.615M	$2.775M
Prepaid Expenses	$4.533M	$5.464M
Receivables	$16.80M	$7.816M
Other Receivables	$0.00	$32.80M
Total Short-Term Assets	$142.9M	$77.72M
YoY Change	83.91%	-38.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.303M	$1.217M
YoY Change	7.07%	-15.07%
Goodwill	$21.21M	$21.21M
YoY Change	0.0%	0.0%
Intangibles	$50.03M	$53.57M
YoY Change	-6.6%	-9.47%
Long-Term Investments
YoY Change
Other Assets	$2.654M	$240.0K
YoY Change	1005.83%	-89.54%
Total Long-Term Assets	$77.73M	$79.48M
YoY Change	-2.2%	-9.69%
TOTAL ASSETS
Total Short-Term Assets	$142.9M	$77.72M
Total Long-Term Assets	$77.73M	$79.48M
Total Assets	$220.7M	$157.2M
YoY Change	40.37%	-26.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.565M	$13.25M
YoY Change	-42.92%	23.87%
Accrued Expenses	$21.14M	$12.57M
YoY Change	68.21%	33.65%
Deferred Revenue	$4.992M	$3.111M
YoY Change	60.46%
Short-Term Debt	$0.00	$19.40M
YoY Change	-100.0%
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$40.70M	$87.65M
YoY Change	-53.56%	287.6%
LONG-TERM LIABILITIES
Long-Term Debt	$71.38M	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$41.31M	$46.20M
YoY Change	-10.58%	26.23%
Total Long-Term Liabilities	$112.7M	$46.20M
YoY Change	143.92%	-37.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.70M	$87.65M
Total Long-Term Liabilities	$112.7M	$46.20M
Total Liabilities	$153.4M	$133.9M
YoY Change	14.57%	-11.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$440.4M	-$369.7M
YoY Change	19.13%	58.8%
Common Stock	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$67.25M	$23.29M
YoY Change
Total Liabilities & Shareholders Equity	$220.7M	$157.2M
YoY Change	40.37%	-26.59%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$17.50M	$6.401M
YoY Change	-373.41%	-132.43%
Depreciation, Depletion And Amortization	$922.0K	$2.033M
YoY Change	-54.65%	16.24%
Cash From Operating Activities	-$38.20M	-$8.335M
YoY Change	358.3%	-70.18%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$5.000M
YoY Change	-100.0%	-111.19%
Cash From Investing Activities	-$261.0K	$4.785M
YoY Change	-105.45%	-110.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$11.00K
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	-$1.022M	-$76.84M
YoY Change	-98.67%	6853.94%
NET CHANGE
Cash From Operating Activities	-$38.20M	-$8.335M
Cash From Investing Activities	-$261.0K	$4.785M
Cash From Financing Activities	-$1.022M	-$76.84M
Net Change In Cash	-$39.59M	-$80.39M
YoY Change	-50.76%	6.85%
FREE CASH FLOW
Cash From Operating Activities	-$38.20M	-$8.335M
Capital Expenditures	$12.00K	$0.00
Free Cash Flow	-$38.21M	-$8.335M
YoY Change	358.44%	-70.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92660
CY2022Q1	dei	City Area Code CityAreaCode	(949)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	284-4555
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	EOLS
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56048990	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106671000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	146256000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16800000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14657000	USD
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38381
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1385614
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Newport Center Drive Suite 1200
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Newport Beach
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	us-gaap	Inventory Net InventoryNet	3615000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	1762000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4533000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5082000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	11309000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	11042000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	142928000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	178799000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1303000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1371000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2537000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2722000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50032000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50625000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2654000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2758000	USD
CY2022Q1	us-gaap	Assets Assets	220662000	USD
CY2021Q4	us-gaap	Assets Assets	257483000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7565000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6091000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21139000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29993000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5000000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1279000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1265000	USD
CY2022Q1	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	5717000	USD
CY2021Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	5314000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	40700000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57663000	USD
CY2022Q1	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	0	USD
CY2021Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	5000000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2010000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2256000	USD
CY2022Q1	us-gaap	Contractual Obligation ContractualObligation	39300000	USD
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation	39426000	USD
CY2022Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	71381000	USD
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	71222000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	23000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	40000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	153414000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	175607000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56041364	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56041364	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55576988	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55576988	shares
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	507733000	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	504757000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-103000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-440383000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-422882000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	67248000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	81876000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	220662000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	257483000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33908000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12241000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13208000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4908000	USD
CY2022Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2021Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33442000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20665000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	468000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	841000	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1316000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1268000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	922000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2033000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	49356000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	4215000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15448000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	8026000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	2048000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	645000	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-968000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17503000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6413000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17501000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	6401000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	103000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17398000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6401000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55731217	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37100897	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55731217	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41104627	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-72958000	USD
CY2021Q1	eols	Stock Issued During Period Values Litigation Settlement StockIssuedDuringPeriodValuesLitigationSettlement	48421000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	39808000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1606000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	6401000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	23289000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	81876000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2959000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17501000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-103000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	67248000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17501000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	6401000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	922000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2033000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2959000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1590000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	465000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	610000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	185000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	166000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	263000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	286000	USD
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	273000	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-17000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1316000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1268000	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-968000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2608000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1254000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5571000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3149000	USD
CY2022Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2021Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-549000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	636000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3454000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1657000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1471000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1808000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8854000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3465000	USD
CY2022Q1	eols	Increase Decrease In Accrued Litigation Settlement IncreaseDecreaseInAccruedLitigationSettlement	-15000000	USD
CY2021Q1	eols	Increase Decrease In Accrued Litigation Settlement IncreaseDecreaseInAccruedLitigationSettlement	0	USD
CY2022Q1	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-232000	USD
CY2021Q1	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-197000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38199000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8335000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2022Q1	us-gaap	Payments For Software PaymentsForSoftware	249000	USD
CY2021Q1	us-gaap	Payments For Software PaymentsForSoftware	215000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	5000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-261000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4785000	USD
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2021Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	76323000	USD
CY2022Q1	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	1039000	USD
CY2021Q1	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	529000	USD
CY2022Q1	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	17000	USD
CY2021Q1	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	11000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1022000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-76841000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-103000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39585000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-80391000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146256000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102562000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106671000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22171000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1781000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	79000	USD
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	39808000	USD
CY2022Q1	eols	Stock Issued For Accrued Litigation Settlement Expense StockIssuedForAccruedLitigationSettlementExpense	0	USD
CY2021Q1	eols	Stock Issued For Accrued Litigation Settlement Expense StockIssuedForAccruedLitigationSettlementExpense	48421000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15448000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-17501000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38199000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106671000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-440383000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company’s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact of current global events, including the COVID-19 pandemic, rising inflation and the Ukrainian-Russian war, is unknown and cannot be reasonably estimated. However, where possible, management has considered the potential impact of COVID-19, rising inflation and the Ukrainian-Russian war, and their respective market impacts, on its estimates and assumptions, and there was not a material impact to the Company’s condensed consolidated financial statements as of and for the three months ended March 31, 2022. The Company’s future assessment of the impact of these events, as well as other factors, could result in material impacts to the Company’s financial statements in future reporting periods.</span></div>
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (“Daewoong”) entered into an agreement (the “Daewoong Agreement”), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company’s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company’s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div>The COVID-19 pandemic continues to evolve, and the severity and magnitude of future outbreaks, could result in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets caused by these or other events, such as the military conflict between Russia and Ukraine and increased inflation, may increase the Company’s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company’s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company’s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div>
CY2021Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2022Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2022Q1	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4992000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7934000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7254000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1515000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2829000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2385000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	465000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	610000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	21000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	165000	USD
CY2020Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	83421000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5000000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5000000	USD
CY2020Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	48421000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2022Q1	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	0	USD
CY2021Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	5000000	USD
CY2021Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17398000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	6401000	USD
CY2022Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2021Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	273000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17398000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	6674000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55731217	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37100897	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	0	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	4003730	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55731217	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41104627	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	44740000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	41546000	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1039000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	529000	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1316000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1268000	USD
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	45017000	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	42285000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	66640000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16608000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50032000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	21208000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	21208000	USD
CY2022Q1	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	87848000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16608000	USD
CY2022Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	71240000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	66390000	USD
CY2022Q1	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	250000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15765000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50625000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q4	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	87598000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15765000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	71833000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2345000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3080000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2987000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2955000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2955000	USD
CY2022Q1	eols	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	35710000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50032000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2714000	USD
CY2021Q1	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	224000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	843000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1953000	USD
CY2022Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9371000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	12447000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3710000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6856000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4992000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7934000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	352000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	595000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2161000	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	21139000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	29993000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	25000000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	25000000	USD
CY2022Q1	eols	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	25000000	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3619000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	71381000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2022Q1	eols	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P36M
CY2022Q1	eols	Lessee Operating Lease Period Of Written Notice Prior To Lease Terminate Date LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate	P12M
CY2022Q1	eols	Lessee Operating Lease Termination Fee Period Of Rent Equivalent LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent	P6M
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	269000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	265000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	24000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	8000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	293000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	273000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	953000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1320000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1377000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	115000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3765000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	476000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3289000	USD
CY2022Q1	us-gaap	Purchase Obligation PurchaseObligation	1931000	USD
CY2020Q4	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2	complaint
CY2020Q4	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	2	plaintiff
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2022Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56041364	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56041364	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.040
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1044640	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2959000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1590000	USD
CY2021Q1	eols	Registration Rights Agreement Selling Period RegistrationRightsAgreementSellingPeriod	P3M
CY2022Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9371000	USD
CY2022Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5000000	USD
CY2022Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	4228000	USD
CY2021Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2169000	USD
CY2022Q1	eols	Payments For Legal Settlements Inventory PaymentsForLegalSettlementsInventory	12635000	USD
CY2021Q1	eols	Payments For Legal Settlements Inventory PaymentsForLegalSettlementsInventory	0	USD

Files In Submission

Name	View Source	Status
0001570562-22-000102-index-headers.html	Edgar Link	pending
0001570562-22-000102-index.html	Edgar Link	pending
0001570562-22-000102.txt	Edgar Link	pending
0001570562-22-000102-xbrl.zip	Edgar Link	pending
a3312210qex101.htm	Edgar Link	pending
eols-20220331.htm	Edgar Link	pending
eols-20220331.xsd	Edgar Link	pending
eols-20220331_cal.xml	Edgar Link	unprocessable
eols-20220331_def.xml	Edgar Link	unprocessable
eols-20220331_htm.xml	Edgar Link	completed
eols-20220331_lab.xml	Edgar Link	unprocessable
eols-20220331_pre.xml	Edgar Link	unprocessable
exhibit311q12022.htm	Edgar Link	pending
exhibit312q12022.htm	Edgar Link	pending
exhibit321q12022.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus, Inc. Stock $eols

2022 Q1 Form 10-Q Financial Statement

#000157056222000102 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus, Inc. Stock $eols

2022 Q1 Form 10-Q Financial Statement

#000157056222000102 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus, Inc. Stock $eols